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Genetic susceptibility contributes to the etiology of sporadic Parkinson’s Disease (PD)
and worldwide studies have found positive associations of polymorphisms in the alpha-
synuclein gene (SNCA) with the risk for PD. However, little is known about the influence
of variants of SNCA in individual traits or phenotypical aspects of PD. Further, there is a
lack of studies with Latin-American samples. We evaluated the association between
SNCA single nucleotide polymorphisms (single nucleotide polymorphisms, SNPs –
rs2583988, rs356219, rs2736990, and rs11931074) and PD risk in a Brazilians sample.
In addition, we investigated their potential interactions with environmental factors and
specific clinical outcomes (motor and cognitive impairments, depression, and anxiety).
A total of 105 PD patients and 101 controls participated in the study. Single locus
analysis showed that the risk allele of all SNPs were more frequent in PD patients
(p < 0.05), and the associations of SNPs rs2583988, rs356219, and rs2736990 with
increased PD risk were confirmed. Further, the G-rs356219 and C-rs2736990 alleles
were associated with early onset PD. T-rs2583988, G-rs356219 and C-2736990 alleles
were significantly more frequent in PD patients with cognitive impairments than controls
in this condition. In addition, in a logistic regression model, we found an association of
cognitive impairment with PD, and the practice of cognitive activity and smoking habits
had a protective effect. This study shows for the first time an association of SNCA
polymorphism and PD in a South-American sample. In addition, we found an interaction
between SNP rs356219 and a specific clinical outcome, i.e., the increased risk for
cognitive impairment in PD patients.
Keywords: Parkinson’s disease, alpha-synuclein, SNCA gene, polymorphism, cognitive impairment, clinical
assessment, Brazil
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INTRODUCTION
Parkinson’s disease (PD) is the second most common
neurodegenerative disease. This condition mainly affects
motor function, but also causes non-motor symptoms (Fahn,
2003; Wirdefeldt et al., 2011; Pihlstrøm et al., 2013). Among
other neurological sings, the cardinal features of this disorder are
bradykinesia, rigidity and resting tremor. In parallel, impairment
of executive functions and the presence of apathy, anxiety, and
depression are the main neuropsychiatric manifestations in PD
patients (Rodriguez-Oroz et al., 2009). The onset of PD is usually
after 50 years old, and a sharp increase of the incidence is seen
after the age of 60 (1% of the population; Lau and Breteler, 2006).
Although PD’s etiology remains unclear, the interaction between
genetic and environmental substrates has been associated
with the development of the disease (Lau and Breteler, 2006;
Wirdefeldt et al., 2011). Among those environmental factors,
several studies pointed the inverse correlation between cigarette
smoking and PD risk (Allam et al., 2004; Li et al., 2015). On
the other hand, history of professional pesticide exposure, rural
living or well water drinking were reported to increase PD risk
(Semchuk et al., 1991; Firestone et al., 2005). In addition, physical
activity (Paillard et al., 2015; Shih et al., 2016), cognitive reserve
(Hindle et al., 2014, 2015) and caffeine intake (Costa et al.,
2010) are suggested as protective factors, but with insufficiently
consistent results.
Genome-wide association studies (GWAS) have identified
single nucleotide polymorphisms (SNP) in many candidate
genes that contribute to PD susceptibility such as microtubule-
associated protein tau (MAPT), leucine-rich repeat kinase
(LRRK2) and alpha-synuclein (SNCA) (Mata et al., 2011; Satake
et al., 2009; Simón-Sánchez et al., 2009; Sharma et al., 2012).
The relevance of SNCA variations for PD risk is already
well established through linkage and GWAS studies. Moreover,
certain polymorphisms of SNCA are among the major risk factors
for sporadic PD (Simón-Sánchez et al., 2009) and have been
correlated with increased plasmatic levels of alpha-synuclein
(Mata et al., 2010).
The presynaptic protein alpha-synuclein is the major
component of the Lewy body, which is the pathological hallmark
of PD (Spillantini et al., 1997, 1998; Trojanowski and Lee,
1998; Xu et al., 2015). The physiological function of alpha-
synuclein implicates molecular mechanisms of dopaminergic
neurotransmission such as regulation of oxidative stress,
maintenance of synaptic function and neuronal trafficking
(Schapira, 2007; Bendor et al., 2013; Eisbach and Outeiro,
2013). The overexpression of alpha-synuclein reduces tyrosine
hydroxylase activity and dopamine release (Perez et al., 2002;
Ozansoy and Basak, 2012), disrupts microtubule-dependent
trafficking (Lee et al., 2006), increases oxidative by complex I
mitochondrial dysfunction (Mullin and Schapira, 2013; Wu-
Chou et al., 2013) and impairs neurotransmitter storage which
leads to cytoplasmic accumulation (Lotharius and Brundin,
2002). Mutant protein can result in increased dopamine
intracytoplasmic concentration, which contributes to raise the
sensitivity to dopamine toxicity by reactive oxygen species
generation (Tabrizi et al., 2000).
Case-control studies in different populations have also
found associations between several SNCA polymorphisms and
increased risk of PD. For example, the dinucleotide repeat REP1
located in SNCA promoter (SNCA-Rep1) and the 3′ untranslated
region (UTR) variants have been broadly investigated (Pals et al.,
2004; Hu et al., 2010; Ritz et al., 2012). Variations in these
regions may confer susceptibility to PD by altering transcription
factor binding sites (Chiba-Falek and Nussbaum, 2001; Chiba-
Falek et al., 2003) and generating or destroying microRNA target
sites, which in turn modifies gene expression (Wang et al., 2008;
Sotiriou et al., 2009; Mccarthy et al., 2011). Several investigations
had focused on the association between SNCA SNPs and PD
in ethnic groups, most of them performed in Caucasian and
Asian populations. Hence, the results may be applicable only for
these groups (Han et al., 2015). To our knowledge, no studies
have investigated associations of SNCA polymorphisms in South
American populations.
Currently, there is much interest in the search for clinical
predictors of motor and non-motor symptoms in PD.
Notwithstanding, most of the gene association studies are limited
to genetic risk factor data. Importantly, the consequences of
genetic variability on clinicalphenotypes, as well the interaction
between genetic and environmental substrates, are poorly
elucidated. Few studies pointed weak or absence of associations
with clinical outcomes such as motor impairment (Ritz et al.,
2012; Markopoulou et al., 2014), anxiety, or depression (Verbaan
et al., 2008; Guo et al., 2014; Chen W. et al., 2015; Cheng et al.,
2016), sleep, and autonomic disorders (Verbaan et al., 2008;
Chen W. et al., 2015), and cognitive impairments (Verbaan
et al., 2008; Guo et al., 2014; Chen W. et al., 2015; Chen Y.P.
et al., 2015; Cheng et al., 2016; Wang et al., 2016). Thus,
there is little information concerning motor and non-motor
symptoms assessment, lifestyle and environmental expositions.
Gene-environmental studies investigate whether environmental
factors such as smoking habits and coffee consumption could
modify genetic associations with PD (Gao et al., 2012; Miyake
et al., 2012; Ritz et al., 2012; Trotta et al., 2012). However, studies
that investigate possible SNCA polymorphisms associations with
specific clinical aspects of PD are inconclusive. Therefore, the
elucidation of the genetic contribution to clinical phenotypes
remains a challenge. In this respect, the description of genetic
predictors and their relationship with other etiological factors
and clinical outcomes is determinant to improve the knowledge
of pathophysiological pathways and help to target the best
therapeutic program.
In the present study, we investigated possible interactions
between polymorphisms in the SNCA gene and PD in a Brazilian
sample, and examined potential associations between these
polymorphisms and environmental factors and specific clinical
outcomes.
SUBJECTS AND METHODS
Patients and Controls
The unrelated sample consisted of 105 PD patients and
101 control subjects recruited from Onofre Lopes University
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Hospital, in Rio Grande do Norte (Northeastern – Brazil)
from June, 2013 to November, 2014. PD was diagnosed by a
neurologist according to UK Parkinson’s Disease Society Brain
Bank Clinical Criteria (Hughes, 2004). Recruitment of control
subjects was conducted in the same hospital at other departments
than the neurology department. Controls were subjects from
the general population without neurological disease and family
history of PD. The groups were matched by age and sex. This
study was approved by the ethical committee of Onofre Lopes
University Hospital (protocol number 04261012.5.1001.5292).
All the patients and controls were requested to sign the written
informed consent.
Clinical Assessment
Case and control subjects filled out a set of eight questionnaires.
Information of demographic variables and medical history, such
as sex, age, education level, age at PD onset and disease duration
were obtained in the baseline interview. Family history was
considered positive until second-degree relatives. A structured
questionnaire of environmental factors delivered information
about risk (pesticide exposition, living in rural areas and well-
water consumption) and protective (smoking habits, coffee
intake, physical exercises and cognitive activities) factors. History
of smoking was defined on basis of self-report as never vs. ever
having smoked at least once a day for at least one year (Miyake
et al., 2012). Coffee consumption was assessed on basis of self-
report and consumption was defined as more than two coffee
cups per day (Trotta et al., 2012). Similarly, self-reported physical
exercises or cognitive actives (i.e., reading, crossword puzzles,
card games, chess, and others) were considered when carried out
at least once a week.
The evaluation of different clinical aspects comprised the
application of the following inventories: (1) PD motor symptoms
were assessed by Unified Parkinson’s Disease Rating Scale
(UPDRS I, II, and III) (Fahn and Elton, 1987), Hoehn & Yahr
scale (HY) (Hoehn and Yahr, 1967) and Schwab and England
Activities Daily Living Scale (SE); (2) emotional status was
assessed by Beck Depression Inventory (BDI) (Beck et al., 1988b)
with a cut-off score of 10 to detect depression (Tröster et al., 1995)
and Beck Anxiety Inventory (BAI) (Beck et al., 1988a) with a
cut-off score of 10 to detect anxiety (Julian, 2011). The severities
of depression and anxiety were determined, according to the
following scores, respectively: moderate (BDI: 19–29 points; BAI:
20–30 points) and severe (BDI: higher than 29 points; BAI: higher
than 30 points); (3) Mini Mental State Examination (Folstein
et al., 1975) and Frontal Assessment Battery (FAB) (Beato et al.,
2007) assessed cognitive functions. Cognitive impairment was
defined by the application of the cut- off MMSE scores taking the
educational level into consideration: 20 for illiterate, 25 for lower
education (1 to 4 years), 27 for middle education (5 to 8 years),
and 28 for high education (greater than 8 years) (Brucki et al.,
2003). All clinical evaluations were conducted during the “on”
state of levodopa treatment.
DNA Extraction and Genotyping
Genomic DNA was extracted from EDTA-containing peripheral
blood samples (commercial kit FlexiGene R© DNA kit, Qiagen,
Germany). Genotyping of SNPs rs2583988 (C > T), rs356219
(A > G), rs2736990 (T > C), and rs11931074 (G > T) in
SNCA gene was performed using real-time TaqMan R© polymerase
chain reaction assay according to the manufacturer’s instructions
(Applied Biosystems, Foster City, CA, United States). Four
samples were lost due to poor quality of DNA. 104 PD patients
and 98 controls were successfully genotyped.
Statistical Analysis
Non-parametric data were presented as median [minimum
value; maximum value]. Inventories scores were compared
between groups with Mann-Whitney and Kruskal-Wallis given
the nonparametric nature of the data. X2 statistics (Fisher
exact test) was used to compare categorical data, calculation
of frequency significance and odds ratio (OR). Parametric
data were presented as mean and standard deviation. T-
student independent test was used to assess differences in
mean age at interview between PD and control groups.
Calculations of Hardy–Weinberg equilibrium, linkage
disequilibrium (LD), estimation of haplotypes and haplotype
frequency were performed by the software Snpstat1. Crude
odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated to estimate risk size for the heterozygotes
and homozygotes for the risk alleles by binary logistic
regression analysis, adjusted for age and gender. The
statistical power calculation was performed using G ∗ Power
statistical program. Statistical significance was defined when
p-values < 0.05.
RESULTS
Study Population
Two hundred and six subjects participated in the study. In PD
group (n = 105, 73 men and 32 women) the mean age was
64.42 years (range: 37–89 years) and in control group (n = 101,
68 men and 33 women) it was 62.98 years (range: 38–88 years),
without significant difference (U = 4632.00, p= 0.260) (Table 1).
The majority of PD and control subjects were married, living
in urban area and had basic education (35.7% of cases and
35.3% of controls had less than four years of education). There
were no differences in percent of subjects in each level of
education between groups (p = 0.486). Most of PD cases
(81.4%) were retired while 49% of controls subjects had a work
activity.
PD Group’s Profile
The mean age of PD onset was 55.7 ± 11.9 years (range 30–87),
with 37 patients (35.2%) classified as early onset (≤50 years).
The mean of disease duration was 8.80 ± 5.78 years (range
1–32) and of treatment duration was 5.6 ± 4.5 years (range
0–21). Seventy patients (69.3%) describe their first symptom as
involuntary tremors. A positive family history was reported by 45
patients (42.9%). Those cases were categorized as “familial”, the
remaining subjects as “sporadic” (Table 1).
1http://bioinfo.iconcologia.net/SNPstats
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TABLE 1 | Profile and frequencies of exposition to environmental factors.
Cases (n = 105) Control (n = 101) Unadjusted OR (95% CI) p
Mean age at interview (years)a 64.42 ± 11.69 62.98 ± 10.04 – 0.259
Mean onset age (years)a 55.7 ± 11.9 – – –
Mean disease duration 8.80 ± 5.78 – – –
Familial history (%) 42 – – –
Early onset (%)b 35.2 – – –
Education (%)
Illiterate 11.9 17.2 – 0.486
Lowc 35.7 35.3
Midlled 15.8 11.1
Highere 36.6 36.4
Risk Factors
Pesticides (%)
No 77.2 73.0 0.79 (0.42–1.51) 0.511
Yes 22.8 27.0
Countryside (%)
No 37.3 40.0 1.12 (0.63–1.97) 0.773
Yes 62.7 60.0
Well-water consumption
No 27.5 25.0 0.88 (0.47–1.65) 0.750
Yes 72.5 75.0
Protective Factors
Coffee consumption (%)
No 71.7 81.4 0.58 (0.29–1.27) 0.106
Yes 28.3 18.6
History of Smoking (%)
No 55.4 51.5 0.85 (0.49–1.48) 0.671
Yes 11.9 20.2
Abstinent 32.7 28.3
Physical Activity (%)
No 54.4 68.0 1.64 (0.92–2.91) 0.110
Yes 43.6 32.0
Cognitive Activity (%)
No 45.5 17.3 0.25 (0.13–0.48) <0.001
Yes 54.5 82.7
aData presented as mean ± standard deviation. Groups compared by independent sample t-test.
b≤50 years
cLess than 4 years of education
dBetween 4 and 8 years of education
e 9 years of education or more
p-value, odds ratios and confidence intervals (CI) calculated by Fisher’s test for frequencies of environmental factors. Chi-square test evaluated frequencies of educational
level. Significant p-values are indicated in bold.
Frequencies of exposition to environmental factors are shown
in Table 1. We found a similar frequency of exposure to
risk factors (pesticide contact, living in countryside and well-
water consumption) and protective factors (coffee consumption,
smoking habits, and physical activities) between groups, without
significant associations with PD risk. Although most of the
subjects reported living in countryside (62.7% in cases and 60%
in controls), there were few reports of pesticide use in agriculture
(22.8% in cases and 27% in controls). There was a low frequency
of reported coffee consumption (28.3% in cases and 18.6% in
controls) and current smokers (11.9% in cases and 20.2% in
controls) in our sample. We found a higher frequency of practice
of cognitive activities in the control group, and this factor showed
a strong protective effect against PD (OR = 0.25; 95% CI =
0.13–0.48).
Clinical Assessment
Performances of PD and control group in the clinical assessment
are described in Table 2. Median of disease progression
measured by Hoehn & Yahr scale was 2.5 [1–5], and 53%
of the patients were in stages III to V. Assessment of motor
activity measured by UDPRS III indicated a significant motor
impairment in PD group [19.0 [0–50] versus 0.0 [0–19];
U = 181.0, p < 0.001]. PD patients also showed greater difficulty
to perform daily living activities (20.0 [3–45 versus 0.0 [0–
12]) when evaluated by UDPRS II (U = 82.5, p < 0.001).
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TABLE 2 | Clinical assessment scores of Pakinson’s disease (PD) patients and
Controls.
PD Control p
Hoehn & Yahr 2.5 [1;5] 0.0 –
UPDRS I 1.0 [0;4] 2.0 [0;11] 0.006
UPDRS II 20.0 [3;45] 0.0 [0;12] <0.001
UPDRS III 19.0 [0;50] 0.0 [0;19] <0.001
SE 70.0 [10; 90] 100.0 [ 60;100] <0.001
MMSE score 23.0 [10;30] 25.0 [8.;30] 0.097
Cognitive impairment (%)a 61.0 57.9 0.663
MMSE
Illiterate 21.0 [10;25] 22.0 [ 8;29] 0.187
Lower 21.0 [11;27] 25.0 [19;30] 0.003
Middle 26.0 [12;29] 25.0 [15;30] 0.904
Higher 26.0 [11;30] 25.0 [13;30] 0.667
FAB 11.0 [2;16] 11.0 [2;18] 0.063
Illiterate 6.0 [2;11] 8.0 [4;16] 0.011
Lower 7.0 [2;16] 9.0 [4;18] 0.027
Middle 13.0 [2;16] 12.0 [2;18] 0.790
Higher 13.0 [2;16] 14.0 [3;18] 0.279
BDI score 14.0 [2;47] 5.0 [0;47] <0.001
Depression (%)b 74.7 29.0 <0.001
BAI score 16.0 [0;47] 7.0 [0;37] <0.001
Anxiety (%)c 72.6 36.0 <0.001
PD, Parkinson’s Disease; UPDRS, Unified Parkinson’s Disease Rating Scale;
SE, Schwab & England Activities Daily Living Scale; MMSE, Mini Mental State
Examination; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory
aApplied cut-off point for education level to MMSE scores (illiterate: 20, lower
education:25, middle education: 27, high education: 28).
b,cPresence of depression and anxiety after applied cut-off points.
Data are reported as median, minimum and maximum values; p-value by Mann–
Whitney test or chi-square for frequencies. Significant p-values are indicated in
bold.
In addition, patients presented a reduction of functional
independence (70.0 [10–90] versus 100.0 [60–100]; U = 296.0,
p < 0001).
Total score of MMSE (PD: 23[10-30] versus Control: 25.0
[8–30]) and FAB PD: 11.0 [2–16] versus control: 11.0 [2–18])
(Table 2), as well as the presence of cognitive impairment (61%
in PD and 57.9% in control group) did not differ between groups
[χ2(1) = 0.243; p = 0.663]. However, we observed a significant
lower score of MMSE in PD group after the stratification of
data by educational levels, which indicates a larger cognitive
impairment in the subgroup of PD patients with lower education
compared to controls with the same level of education (21.0
[11–27] versus 25.0 [19–30]) (U = 336.50, p = 0.003). Similar
effect of education level was found after the stratification of
FAB scores. Regarding emotional evaluation, PD group had
significantly higher scores in BDI (11.0 [2–47] versus 5.0 [4–74])
and BAI (16.0 [0–47] versus 7.0 [0–37]) than the control group.
Furthermore, levels of depression and anxiety were significantly
more severe in the PD group (BDI: 24.2% moderate and 10.5%
severe; BAI: 26.3% moderate and 9.5% severe, respectively),
which resulted in a higher frequency of depression [74.7%
versus 2%; χ2(1) = 40.971, p < 0.001] and anxiety symptoms
[72.6% versus 36.0%; χ2(1) = 26.305, p < 0.001] in the PD
group.
SNP Assessment
Deviation from Hardy-Weinberg equilibrium was not observed
for any of the SNPs. 104 participants in PD group and
98 in control group were genotyped for all SNPs. Linkage
disequilibrium (LD) structure of SNCA indicates a significant
pairwise value of LD between rs356219 and rs2736990
(r2 = 0.888, D′ = 0.988, p < 0.001). Allele and genotype
distributions of SNPs in patients and controls are summarized in
Table 3.
Single locus analysis of SNPs rs2583988, rs356219, rs2736990,
and rs11931074 showed that the risk alleles of each SNP, as well as
homozygotes for these alleles, were more frequent in PD patients
compared to controls. Logistic regression analysis confirmed
a significant association between risk genotypes and PD for
rs2583988 (OR= 12.20, 95%IC: 1.52–97.58, p= 0.018), rs356219
(OR= 2.94, 95%IC: 1.29–6.67, p= 0.010), rs2736990 (OR= 2.65,
95%IC: 1.16–2.60, p = 0.024), that remained significant after
correction for the covariates age and sex. There was no significant
difference in genotype distribution for rs11931074 between
patients and controls (OR = 1.55, 95% IC: 0.58–1.14, p = 0.379).
Statistical power calculation applied to the sample size used in
this research indicate a detection of a gene-disease association for
SNPs rs2583988, rs356219, rs2736990 with values of OR higher
than 2.60, with an accuracy between 68 and 85% under the
recessive model.
Age at disease onset was not different between the three
genotypes for the SNPs evaluated (data not shown). However,
frequency analyses of risk allele in patients with early disease
onset (EOPD) indicated a significant higher frequency of
G-rs356219 and C-rs2736990 in patients when compared to
controls (p = 0.040; p = 0.028, respectively), with OR indicating
an increased risk of 1.82 (95%IC: 1.05–3.14) and 1.88 (95%IC:
1.07–3.29), respectively (Table 4).
The frequencies of risk alleles in cases and control groups
considering only the subjects that presented cognitive
impairment, anxiety and depression by clinical assessment
were described in Table 4. There were no differences in the
frequency of risks alleles between groups considering presence
of depression and anxiety. However, the risk alleles T-rs2583988,
G-rs356219, and C-2736990 had higher frequencies in patients
(31, 67, and 70%, respectively) than controls (16, 47, and 52%)
with cognitive impairments (ORs= 2.21 to 2.39). When patients
were stratified by genotypes, Kruskal-Wallis test detected no
differences in the scores of disease progression (HY stage), daily
living activities (UPDRS-II score) or motor assessment (UPDRS-
III score) between genotypes in each SNP and assessment (data
not shown).
Analyses restricted to patients were performed to investigate
whether risk genotypes influenced clinical outcomes (cognitive
impairments, anxiety and depression). Table 5 shows the
significant and marginal associations with each SNP in SNCA by
binary logistic regression. There was no significant association
with motor impairment. Both rs356219 heterozygotes
(OR = 4.74, 95% CI: 1.27–17.75, p < 0.05) and homozygotes
(OR = 5.74, 95% CI: 1.42-23.21, p < 0.05) had significantly
increased risk for cognitive impairment, while the CT-rs2736990
(OR = 3.87, 95% IC: 0.97–15.36, p = 0.054) and CC-rs2736990
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TABLE 3 | Genotypic and allelic frequencies of single nucleotide polymorphisms (SNPs) in alpha-synuclein gene (SNCA) gene in PD cases (n = 104) and controls
(n = 98).
Genotype PD n(%) Control n(%) Unadjusted analysis Adjusted analysis
OR (95% CI) p OR (95% CI) p
rs2583988
C/C 55(53) 61 (62) 1.00 (reference) 1.00 (reference)
C/T 38 (37) 36 (37) 1.17 (0.65–2.09) 0.597 1.19 (0.65–2.15) 0.562
T/T 11 (11) 1 (1) 12.20 (1.52–97.58) 0.018 12.35 (1.52–99.88) 0.018
C allele 148 (71.1) 158 (80.6) 1.68 (1.06–2.68) 0.026
T allele 60 (28.8) 38 (19.3)
rs356219
A/A 16 (15) 26 (27) 1.00 (reference) 1.00 (reference)
G/A 50 (48) 51 (52) 1.59 (0.76–3.32) 0.214 1.60 (0.76–3.35) 0.209
G/G 38 (37) 21 (21) 2.94 (1.29–6.67) 0.010 2.94 (1.29–6.72) 0.010
A allele 82 (39.4) 103 (52.5) 1.70 (1.14–2.52) 0.008
G allele 126 (60.5) 93 (47.4)
rs2736990
T/T 14 (13) 19 (19) 1.00 (reference) 1.00 (reference)
T/C 43 (41) 55 (56) 1.06 (0.47–2.35) 0.884 1.18 (0.52–2.66) 0.687
C/C 47 (45) 24 (24) 2.65 (1.13–6.20) 0.024 2.73 (1.15–6.48) 0.022
T allele 71 (34.1) 93 (47.4) 1.74 (1.16–2.60) 0.006
C allele 137 (65.8) 103 (52.5)
rs11931074
G/G 54 (52) 61 (62) 1.00 (reference) 1.00 (reference)
G/T 39 (38) 29 (30) 1.51 (0.83–2.78) 0.175 1.52 (0.83–2.80) 1.70
T/T 11 (11) 8 (8) 1.55 (0.58–1.14) 0.379 1.56 (0.58–4.18) 0.377
G allele 146 (70.1) 151 (77.0) 1.40 (0.89–2.19) 0.138
T allele 61 (29.3) 45 (22.9)
PD, Parkinson’s disease; OR, odds ratio; CI, confidence interval; p, significance level.
Significant p-values are indicated in bold.
(OR = 3.84, 95% IC: 0.96–15.30, p = 0.056) genotypes presented
a trend toward to increased risk of the same outcome. No
association of rs2583988 genotypes were found for this outcome.
Conversely, TT-rs2583988 genotype significantly reduced the
risk of depression (OR = 0.21, 95% CI: 0.04–0.97, p = 0.046)
and had a marginal significance for reduced risk of anxiety
(OR = 0.24, 95% CI: 0.05–1.07, p = 0.061). There was no
significant association for rs2583988 heterozygote genotype and
anxiety or depression. The SNPs rs356219 and rs2736990 had no
association with these outcomes.
TABLE 4 | Comparisons of risk allele frequencies between case and control with non-motor clinical outcomes.
Outcomes rs2583988 rs356219 rs2736990
T allele (%) OR (95%CI) p G allele (%) OR (95%CI) p C allele (%) OR (95%CI) p
Age at onset
EOPD 17 (23.0) 1.24 (0.64–2.36) 0.503 46 (62.0) 1.82 (1.05–3.14) 0.040 50 (68.0) 1.88 (1.07–3.29) 0.028
Controls 38 (19.3) 93 (47.4) 79 (80.6)
Cognitive impairment
PD 34 (31.0) 2.39 (1.25–4.58) 0.010 72 (67.0) 2.22 (1.29–3.84) 0.004 76 (70.0) 2.21(1.26–3.85) 0.005
Controls 18 (16.0) 53 (47.0) 58 (52.0)
Anxiety
PD 31 (23.0) 1.29 (0.62–2.66) 0.591 81 (60.0) 1.47 (0.82–2.63) 0.235 89 (65.0) 1.63 (0.55–4.85) 0.398
Controls 13 (19.0) 55 (40.0) 38 (54.0)
Depression
PD 34 (24.0) 1.31 (0.61–2.81) 0.574 80 (57.0) 1.24 (0.66–2.31) 0.527 89 (64.0) 1.59 (0.88–2.87) 0.132
Controls 11 (20.0) 29 (52.0) 32 (57.0)
OR, odds ratio; CI, confidence interval; p, significance level; EOPD, early onset Parkinson’s disease; PD, Parkinson’s disease.
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TABLE 5 | Binary logistic regression for risk genotypes predicting cognitive,
anxiety, and depression in PD patients.
B SE Wald df OR (95%CI) p
Cognitive impairment
rs2736990
CT 1.355 0.703 3.714 1 3.87 (0.97–15.36) 0.054
CC 1.346 0.705 3.641 1 3.84 (0.96–15.30) 0.056
Constant –2.451 1.409 3.025 1 0.089
rs356219
GA 1.558 0.673 5.363 1 4.74 (1.27–17.75) 0.021
GG 1.748 0.713 6.016 1 5.74 (1.42–23.21) 0.014
Constant –2.668 1.407 3.598 1 0.058
Anxiety
rs2583988
CT –0.490 0.515 0.905 1 0.61 (0.22–1.68) 0.341
TT –1.427 0.763 3.501 1 0.24 (0.05–1.07) 0.061
Constant 3.364 1.474 5.212 1 0.022
Depression
rs2583988
CT 0.106 0.540 0.039 1 1.12 (0.38–3.20) 0.844
TT –1.520 0.762 3.983 1 0.21 (0.04–0.97) 0.046
Constant 0.162 1.363 0.014 1 0.905
B, regression coefficient; SE, standard error; df, degrees of freedom; OR, odds
ratio; CI, confidence interval; p, significance level. Significant p-values are indicated
in bold. Only significant and marginally significant associations are shown.
The best logistic regression models (with case or control as
dependent variable) performed to investigate genotypes, clinical
aspects and environmental factors in prediction of disease are
represented in Table 6. TT-rs2583988 (OR = 16.25, 95%IC:
1.72–152.97, p = 0.015) and CC-rs2736990 (OR = 2.37, 95%IC:
1.10–5.03, p = 0.026) risk genotypes were associated with
increased PD risk. There was no significant improvement in
the fit of the model by addition of rs356219 and rs11931074.
Higher scores in BDI (OR = 1.16, 95%IC: 1.10–1.22, p < 0.001)
and presence of cognitive impairment (OR 2.27, 95%IC: 1.03–
4.98, p = 0.040) were directly associated with increased
risk of disease. Conversely, practice of cognitive activity
(OR = 0.37, 95%IC: 0.16–0.84, p = 0.019) and smoking habits
(OR = 0.45, 95%IC: 0.21–0.97, p = 0.042) had a protective effect
against PD.
Logistic regression analysis revealed an association with the
number of risk alleles and the presence of disease (OR = 1.27,
95% CI = 1.06–1.53, p = 0.009), indicating a cumulative
effect. Finally, haplotype analysis result in two blocks with
significant association with PD. Table 7 shows the estimated
frequency of each haplotype for cases and controls when all four
markers are considered. Estimated odds ratios and associated
95% CIs indicate that haplotype T-rs2583988 + G-rs356219
+ C-rs2736990 + T-rs11931074 had a greater risk for PD
(OR= 2.51, 95%IC: 1.37–4.58, p= 0.003) than CGCT haplotype
(OR= 1.85, 95%IC: 1.12–3.05, p= 0.017).
DISCUSSION
The present study investigated the association between four
variants of the SNCA gene and clinical outcomes in Parkinson’s
disease patients compared to controls in a Brazilian sample.
The risk alleles and the risk genotypes were significantly
more frequent in cases than in controls and the PD risk
associations for SNPs rs2583988, rs356219, and rs2736990 were
confirmed for the homozygote genotype. Furthermore, rs356219
and rs2736990 demonstrated a similar frequency in cases,
corroborating the positive correlation for the pairs rs356219
and rs2736990. Carriers of risk allele T-rs2583988, G-rs356219,
and C-rs2736990 were significantly more frequent in cases than
in controls with cognitive impairments. Regression analysis
suggested associations between risk alleles and clinical outcomes
and the contribution of environmental factors for PD risk.
Parkinson’s disease is a neurodegenerative, chronic, and
progressive disease characterized by the presence of motor
(tremor, bradykinesia, rigidity, and postural instability) and
non-motor (mood disturbs, cognitive alterations, sleep,
and autonomic dysfunctions) symptoms (Lauterbach, 2004;
Wirdefeldt et al., 2011). Studies show higher prevalence of
cognitive deficits and depression in PD (Reijnders et al., 2009;
Kehagia et al., 2010) and there is a clinical association between
the two kinds of symptoms (Chagas et al., 2014). Our PD sample
presented moderate motor impairment, higher prevalence of
anxiety and depression symptoms and a similar frequency of
cognitive impairment compared to control group. Cognitive
impairment is a usual finding in elderly population (Ward et al.,
2012) which can explain the higher frequency of this outcome
TABLE 6 | Binary logistic regression model for SNPs genotypes, clinical variables, and environmental factors predicting PD.
Variables B SE Wald df OR (95% CI) p
TT-rs2583988 2.788 1.144 5.942 1 16.25 (1.72 – 152.97) 0.015
CC-rs2736990 0.866 0.389 4.955 1 2.37 (1.10 – 5.03) 0.026
BDI 0.148 0.027 29.499 1 1.16 (1.10 – 1.22) <0.001
Cognitive Impairment 0.943 0.400 5.558 1 2.27 (1.03 – 4.98) 0.040
Cognitive Activity − 0.983 0.417 5.547 1 0.37 (0.16 – 0.84) 0.019
Smoking − 0.784 0.385 4.147 1 0.45 (0.21 – 0.97) 0.042
Constant − 0.780 1.173 0.0442 1 0.334
B, regression coefficient; SE, standard error; df, degrees of freedom; OR, odds ratio; CI, confidence interval; p, significance level; BDI, Beck Depression Inventory score.
Data adjusted for sex and age. Significant p-values are indicated in bold.
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in controls, and also highlight a difficulty in identifying typical
cognitive alterations of PD. Furthermore, we observed an effect
of educational levels on our results. The patients with lower
education presented a larger degree of cognitive impairment than
controls with this same educational level. In a longitudinal study,
Hindle et al. (2015) demonstrated that PD patients with a higher
cognitive reserve had a better performance in cognitive tests.
In addition, educational experiences are essential to attenuate
age-related cognitive decline, and a major protective factor
in dementia (Stern, 2009). Similarly, the practice of cognitive
activities was associated with decreased risk for PD in our
regression model.
Environmental factors have been related with PD in
epidemiologic researches (Lau and Breteler, 2006; Wirdefeldt
et al., 2011). Toxins as MPTP, herbicide paraquat and pesticide
rotenone are selective complex I inhibitor and induce neuronal
degeneration demonstrated in vivo (Betarbet et al., 2000; Lima
et al., 2012) and in vitro (Chun et al., 2001; Uversky et al.,
2002; Giordano et al., 2012) studies. Studies on the association
between environmental toxins and the risk for PD present
inconsistent results when rural living, pesticide use and well-
water consumption are assessed (Allam et al., 2005; Firestone
et al., 2005). In contrast, habits as cigarette smoking (Allam et al.,
2004; Li et al., 2015) and caffeine intake (Costa et al., 2010) have
been linked to protective effects, even though the mechanisms
underlying these protective effects remain to be clarified. In
our study, the frequencies of exposure to environmental factors
were similar in cases and controls, which prevented significant
associations with the disease. However, cognitive activities as
reading, playing cards, board games and crossword puzzles were
more frequent in controls, which suggests a protective role.
To our knowledge, history of cognitive stimulation through
leisure cognitive activities as a protective factor to PD has
not been previously described in the literature. In this respect,
the association of cognitive activities and a possible decreased
risk of PD described in the present study is a new finding.
However, this conclusion is limited because our protocol did
not allow a precise description of type, frequency, intensity,
and other aspects of the self-reported cognitive activities. It
is worth mention that a recent experimental study showed
that environmental stimulation facilitated motor recovery and
prevented cognitive impairment in a mice model of PD
(Campêlo et al., 2017). Thus, although not conclusive, the present
finding encourages investigations regarding the protective role
of cognitive activities in PD, possibly by prospective clinical
studies.
Despite the consistent importance of environmental factors
in PD etiology, most genetic association studies have not
incorporated gene-environmental interactions in the researches.
The interaction of smoking habits and coffee consumption
and SNCA variations have been investigated, but had provided
inconsistent results (De Palma et al., 1998; Gao et al., 2012;
Miyake et al., 2012; Ritz et al., 2012; Trotta et al., 2012).
SNPs rs2583988 and rs356219 had no association with coffee
drinking and cigarette smoking when investigated in an Italian
sample (Trotta et al., 2012). Similarly, the SNPs rs2736990 and
rs11931074 did not demonstrate significant results in a North
American study (Gao et al., 2012). However, a study in a
Japanese sample reported addictive interactions between SNP
rs356219 and smoking for increased risk of PD in subjects with
GG- rs356219 genotype who had never smoked (Miyake et al.,
2012). One of the biological mechanisms proposed to explain
the protective effect of smoking is that nicotine inhibits alpha-
synuclein fibrillation and stabilizes soluble oligomeric forms
(Hong et al., 2009). In our sample, the logistic regression model
including cognitive activities and smoking habits within TT-
rs2583988 and CC-rs2736990 genotypes revealed a protective
effect for PD. Taking together, these results suggest that nicotine
might neutralize the detrimental effect of the risk-associated
genotypes of rs2583988 and rs27366990, and a higher cognitive
stimulation might be protective against PD in individuals with
the risk genotypes.
Genetic data supports the role of alpha-synuclein in the
pathogenic process of PD. Duplications and triplications of
SNCA and a higher production of alpha-synuclein correlate
with disease severity (Chartier-Harlin et al., 2004; Ibáñez et al.,
2004). However, these mutations of SNCA are rare and the
role of common variants are investigated as modifiers of
PD susceptibility. Case-control studies have linked SNCA to
sporadic PD susceptibility using SNPs analysis. Two major
linkage disequilibrium blocks in SNCA gene had been proposed
(Mueller et al., 2005; Myhre et al., 2008): a 5′ block that extends
to promoter-enhancer region to exon 4 and a 3′ block that
comprises intron, 3′ untranslated region, and the 3′ end region
of the gene. Associations between SNPs rs2583988 in 5′ region
(Pals et al., 2004; Winkler et al., 2007; Heckman et al., 2012; Trotta
et al., 2012), rs2736990 in intron 4 (Mata et al., 2011; Heckman
et al., 2012; Miyake et al., 2012; Alieva et al., 2013; Guo et al., 2014;
Davila-Ortiz de Montellano et al., 2016), rs356219 (Lazzarini
et al., 1994; Mata et al., 2010, 2011; Botta-Orfila et al., 2011; Wider
et al., 2011; Trotta et al., 2012; Brockmann et al., 2013; Emelyanov
et al., 2013), and rs11931074 (Gao et al., 2012; Wu-Chou et al.,
2013) in 3′ end were demonstrated by recent studies. A meta-
analysis confirmed the risk association of rs2583988, rs356219,
and rs11931074 variants and PD susceptibility, performed in
dominant and recessive genetic models (Han et al., 2015).
Of notice, the majority of these studies were performed in
Caucasian and Asian populations. Data from Latin American
populations are quite recent (Davila-Ortiz de Montellano et al.,
2016; García et al., 2016), and show associations for rs3857059,
rs356220, rs356203, rs7684318, and rs2736990 variants and
TABLE 7 | Estimated haplotype frequencies for SNPs rs2583988, rs356219,
rs2736990, and rs11931074 in SNCA gene.
Haplotypea Frequency in
cases (%)
Frequency in
controls (%)
OR (95% CI) p
CATG 32.1 45.7 (reference) –
CGCT 29.3 22.9 1.85 (1.12 – 3.05) 0.017
TGCG 26.3 17.5 2.51 (1.37 – 4.58) 0.003
aHaplotype is defined by rs2583988– rs356219– rs2736990– rs11931074.
Adjusted for sex and age.
OR, odds ratio; CI, confidence interval; p, significance level. p-value uncorrected
for multiple testing.
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PD in Mexican samples. Further, no prior study investigated
these associations in Brazilians, or even in a South American
population. Our findings were in agreement with the literature,
indicating a higher PD risk for homozygote genotypes in our
sample for all SNPs studied, except for rs11931074 that had no
significant association with the disease. The Brazilian population
is one of the most heterogeneous populations in the world
and such ethnical heterogeneity creates a particular background.
Variations in our findings in comparison to other studies can be
explained by differences in the genetic backgrounds (Dahodwala
et al., 2009). Although this feature can be a limitation due
to the lack of a straight biological category, several countries
in Latin America and worldwide have a multiethnic profile,
which reinforces the need of genetic association studies in
heterogeneous populations.
Genetic polymorphisms may contribute to specific disease
characteristics and play an important role in phenotypic diversity
of PD. Age at onset of PD is a predictor of progression and
mortality (Wirdefeldt et al., 2011) and has been associated
with multiple SNPs in several studies (Rajput et al., 2009;
Yu et al., 2010; Botta-Orfila et al., 2012; Brockmann et al.,
2013; Pan et al., 2013; Cardo et al., 2014; Huang et al., 2015).
We found a significantly higher frequency of the G-rs356219
and C-rs2736990 risk alleles in patients with earlier onset
compared to controls. Similarly, case-control studies in Germanic
(Brockmann et al., 2013) and Chinese (Pan et al., 2012) samples
showed that G-rs356219 and C-rs2736990 alleles significantly
contributed to earlier age onset. In contrast, a lack of association
was observed in Italians (Trotta et al., 2012) and North
Americans (Mata et al., 2011; Heckman et al., 2012), which
suggest the participation of other modifying factors in age onset
across different populations. Therefore, the contributions of these
polymorphisms to age onset remain unclear. We speculate that
increased expression of alpha-synuclein protein may result in an
early manifestation of PD symptoms.
Studies have investigated the functional effects of the different
SNCA SNPs on gene expression in brain tissues and protein levels
in blood samples, but the results were inconsistent (Fuchs et al.,
2008; Linnertz et al., 2009; Mccarthy et al., 2011; Alieva et al.,
2013; Cardo et al., 2014). For example, a study with a transgenic
mouse model demonstrated that REP1 variants in 5′ region affect
the regulation of transcriptional activity (Cronin et al., 2009).
Human studies demonstrated reduction of SNCA-mRNA levels
in brain tissues and protein levels in blood in the absence of REP1
risk allele (Fuchs et al., 2008; Linnertz et al., 2009). Despite some
evidence of correlations between rs2583988 and REP1 variants
(Pals et al., 2004; Winkler et al., 2007; Myhre et al., 2008), no
significant associations of rs2583988 were found for assessment of
blood protein levels (Fuchs et al., 2008) or SNCA-mRNA (Fuchs
et al., 2008; Linnertz et al., 2009; Alieva et al., 2013).
For the intronic SNP rs2736990, an investigation of gene
expression revealed a trend toward lower levels of SNCA-mRNA
in blood samples of PD patients (Alieva et al., 2013), but in
healthy subjects the T allele was correlated with higher levels of
the isoform SNCA112-mRNA in frontal cortex tissue samples.
SNPs rs356219 and rs11931074 are part of 3′ block and
variants in this region may affect post-transcriptional regulation
factors, such as biding sites of mRNA, and impair RNA
processing or stability and gene or protein expression (Linnertz
et al., 2009; Venda et al., 2010; Elbaz et al., 2011; Mccarthy
et al., 2011). For rs356219, the heterozygote genotype was
correlated with higher levels of mRNA in substantia nigra
of PD cases (Fuchs et al., 2008). Further, G allele carriers
presented higher levels of the SNCA112-mRNA isoform in
frontal cortex (Mccarthy et al., 2011). However, a divergent result
was found by Linnertz et al. (2009) that showed a correlation
between higher levels of SNCA-mRNA and the protective allele
A.
As mentioned, literature supports that polymorphisms in
the SNCA gene increase genetic susceptibility to sporadic
PD and suggests an increased expression of alpha-synuclein.
Despite disease severity (rapid cognitive decline, severe non-
motor symptoms, more widespread neurodegeneration and
faster disease progression) is related to increased alpha-synuclein
expression in familial PD (Venda et al., 2010), there is
a lack of evidence regarding the SNCA variants’ influence
on specific clinical outcomes. Previous studies that assessed
associations between polymorphisms and motor impairment
and disease progression (Ritz et al., 2012; Markopoulou et al.,
2014; Cheng et al., 2016; Davis et al., 2016; Wang et al.,
2016), cognitive functions (Goris et al., 2007; Guo et al.,
2014; Markopoulou et al., 2014; Chen W. et al., 2015;
Wang et al., 2016) and presence or absence of anxiety and
depression (Guo et al., 2014; Chen W. et al., 2015; Cheng
et al., 2016; Dan et al., 2016) present poorly consistent
results.
In our study, no associations were observed regarding the
distribution of risk allele and presence of depression or anxiety.
Nevertheless, here we indicate that the TT- rs2583988 genotype
has a protective effect against these outcomes in patients. In
contrast, a study with a Chinese sample found a decreased risk
of depression in carriers of REP1 risk homozygote genotype and
a correlation with UPDRS part II score, motor fluctuation and
female sex in prediction of PD depression (Dan et al., 2016).
Concerning cognitive aspects, T-rs2583988, C-rs2736990, and
G-rs356219 risk alleles were more frequent in cases than controls
with cognitive impairment, indicating a greater risk of this
outcome in PD. Furthermore, we found an association of
cognitive impairment with risk of PD in the logistic regression
model. An unexpected found for REP1 genotypes was described
in a longitudinal North American study: PD cases with higher
REP1 scores were associated with better motor function and
reduced risk of cognitive impairments (Markopoulou et al.,
2014). These data highlight a possible dual effect or time-
dependent role for SNCA variants.
Regarding motor aspects, a cohort study with American
patients (Ritz et al., 2012) demonstrated an increased risk of faster
decline of motor function in carriers of the REP1 263bp promoter
variant and G-rs356165 allele. In our transversal study, we did
not found correlations between genotypes and severity of motor
symptoms in the patients.
Our study had some limitations. Environmental data were
self-reported, which could provide a misclassification. Further,
the MMSE used to assess cognitive impairment may not be
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the limited number of patients, the power analysis indicated a
moderate statistical power. Irrespective, it would be interesting
to expand the sample to reinforce the results. Indeed, the few
conflicting results may be explained by the small sample size
and differences in genetic background among different ethnic
populations, as mentioned.
CONCLUSION
This study confirms the association between PD and SNCA
SNPs and haplotypes in a Brazilian population. Further, the
data provide evidence that the SNCA variants are associated
with increased risk of cognitive impairment in PD patients.
Therefore, our results encourage the investigation of associations
between genetic variants in SNCA and specific clinical outcomes.
Phenotypic studies and functional assays, with a large sample and
different ethnicities should be performed to confirm and specify
the nature of the associations.
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